The schedule mirrors the clinical-trial protocols that drove substantial weight loss around 20% of body weight over 72 weeks on the 15 mg dose [2] while holding gastrointestinal effects down through gradual escalation [1] [4]
They cover complementary parts of tissue repair BPC-157 drives local blood-vessel formation and growth-factor signalling [1], while TB-500 supports cell migration and angiogenesis through actin regulation [2]
Their impact in the disease initiation and progression needs further investigation in vivo , but in general, these modifications in mutant ATXN3 were shown to modulate its stability, subcellular localization, enzymatic activity, neuroprotective function, self-assembly, its interaction affinity with molecular partners, and/or pathogenicity
Additionally, it activates calcitonin receptor and receptor activity-modifying protein complexes